The role of neuropeptide Y in orexin-induced hypothalamic-pituitary-adrenal activation

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The role of neuropeptide Y (NPY) in the mediation of orexin-induced hypothalamic-pituitary-adrenal (HPA) activation was investigated in the rat. The HPA system was stimulated by intracerebroventricular (i.c.v.) administration of orexin-A or orexin-B (140 or 280 pmol, respectively) and the plasma concentration of corticosterone was used as an index of the degree of activation. i.c.v. pretreatment with NPY antagonist or NPY antiserum (30 min or 24 h before orexin administration, respectively) inhibited the orexin-induced corticosterone release. The inhibitory actions of the antagonist and the antiserum were revealed by the dose-response curve; the highest concentrations practically abolished the HPA activation evoked by the orexins. These data suggest that the HPA system-stimulating effect of the orexins may be mediated by NPY.

Original languageEnglish
Pages (from-to)438-441
Number of pages4
JournalJournal of Neuroendocrinology
Volume13
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Neuropeptide Y
Pituitary-Adrenal System
Corticosterone
Immune Sera
Orexins

Keywords

  • Hypothalamic-pituitary-adrenal system
  • Neuropeptide Y
  • Orexin-A
  • Orexin-B

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)

Cite this

@article{9c5c951a1cc04b2fae89156e741d0210,
title = "The role of neuropeptide Y in orexin-induced hypothalamic-pituitary-adrenal activation",
abstract = "The role of neuropeptide Y (NPY) in the mediation of orexin-induced hypothalamic-pituitary-adrenal (HPA) activation was investigated in the rat. The HPA system was stimulated by intracerebroventricular (i.c.v.) administration of orexin-A or orexin-B (140 or 280 pmol, respectively) and the plasma concentration of corticosterone was used as an index of the degree of activation. i.c.v. pretreatment with NPY antagonist or NPY antiserum (30 min or 24 h before orexin administration, respectively) inhibited the orexin-induced corticosterone release. The inhibitory actions of the antagonist and the antiserum were revealed by the dose-response curve; the highest concentrations practically abolished the HPA activation evoked by the orexins. These data suggest that the HPA system-stimulating effect of the orexins may be mediated by NPY.",
keywords = "Hypothalamic-pituitary-adrenal system, Neuropeptide Y, Orexin-A, Orexin-B",
author = "M. J{\'a}szber{\'e}nyi and E. Bujdos{\'o} and G. Telegdy",
year = "2001",
doi = "10.1046/j.1365-2826.2001.00654.x",
language = "English",
volume = "13",
pages = "438--441",
journal = "Journal of Neuroendocrinology",
issn = "0953-8194",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The role of neuropeptide Y in orexin-induced hypothalamic-pituitary-adrenal activation

AU - Jászberényi, M.

AU - Bujdosó, E.

AU - Telegdy, G.

PY - 2001

Y1 - 2001

N2 - The role of neuropeptide Y (NPY) in the mediation of orexin-induced hypothalamic-pituitary-adrenal (HPA) activation was investigated in the rat. The HPA system was stimulated by intracerebroventricular (i.c.v.) administration of orexin-A or orexin-B (140 or 280 pmol, respectively) and the plasma concentration of corticosterone was used as an index of the degree of activation. i.c.v. pretreatment with NPY antagonist or NPY antiserum (30 min or 24 h before orexin administration, respectively) inhibited the orexin-induced corticosterone release. The inhibitory actions of the antagonist and the antiserum were revealed by the dose-response curve; the highest concentrations practically abolished the HPA activation evoked by the orexins. These data suggest that the HPA system-stimulating effect of the orexins may be mediated by NPY.

AB - The role of neuropeptide Y (NPY) in the mediation of orexin-induced hypothalamic-pituitary-adrenal (HPA) activation was investigated in the rat. The HPA system was stimulated by intracerebroventricular (i.c.v.) administration of orexin-A or orexin-B (140 or 280 pmol, respectively) and the plasma concentration of corticosterone was used as an index of the degree of activation. i.c.v. pretreatment with NPY antagonist or NPY antiserum (30 min or 24 h before orexin administration, respectively) inhibited the orexin-induced corticosterone release. The inhibitory actions of the antagonist and the antiserum were revealed by the dose-response curve; the highest concentrations practically abolished the HPA activation evoked by the orexins. These data suggest that the HPA system-stimulating effect of the orexins may be mediated by NPY.

KW - Hypothalamic-pituitary-adrenal system

KW - Neuropeptide Y

KW - Orexin-A

KW - Orexin-B

UR - http://www.scopus.com/inward/record.url?scp=0035037711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035037711&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2826.2001.00654.x

DO - 10.1046/j.1365-2826.2001.00654.x

M3 - Article

C2 - 11328454

AN - SCOPUS:0035037711

VL - 13

SP - 438

EP - 441

JO - Journal of Neuroendocrinology

JF - Journal of Neuroendocrinology

SN - 0953-8194

IS - 5

ER -